Vincristine sulfate liposomal injection for acute lymphoblastic leukemia

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 4361-4369

  Soosay Raj, Trisha A ^a   Smith, Amanda M ^b   Moore, Andrew S ^a,b  

^a LADY CILENTO CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Acute lymphoblastic leukemia; Chemotherapy; Liposomes; Sphingosomal vincristine; Vincristine sulfate liposomal injection

Indexed keywords

ANTIEMETIC AGENT; ANTIRETROVIRUS AGENT; APREPITANT; CARBAMAZEPINE; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN A; DISTEAROYLPHOSPHATIDYLCHOLINE; DRUG METABOLITE; ERYTHROMYCIN; LIPOSOME; MACROGOL; NANOPARTICLE; NIFEDIPINE; PHENYTOIN; PHOSPHATIDYLCHOLINE; PYRROLE DERIVATIVE; SPHINGOMYELIN; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; AUTONOMIC NEUROPATHY; BCR ABL1 GENE; CANCER PATIENT; CHILDHOOD LEUKEMIA; CONSTIPATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENCAPSULATION; EPENDYMOMA; FOOD AND DRUG ADMINISTRATION; GENE; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER DYSFUNCTION; LYMPHOBLASTOMA; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NANOPHARMACEUTICS; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PHYSICAL CHEMISTRY; REVIEW; RHABDOMYOSARCOMA; SENSORY NEUROPATHY; SIDE EFFECT; SLOW RELEASE FORMULATION; STANDING; THERAPEUTIC ERROR; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHEMOTHERAPY; LIPOSOMES; SPHINGOSOMAL VINCRISTINE; VINCRISTINE SULFATE LIPOSOMAL INJECTION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; LIPOSOMES; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; VINCRISTINE; YOUNG ADULT;

EID: 84887367945     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S54657     Document Type: Review

References (56)

1. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381(9881):1943-1955.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010. Updated June 14, 2013. Available from: http://seer.cancer.gov/csr/1975_2010/. Accessed October 8, 2013.
3. Svendsen AL, Feychting M, Klaeboe L, Langmark F, Schuz J. Time trends in the incidence of acute lymphoblastic leukemia among children 1976-2002: a population-based Nordic study. J Pediatr. 2007;151(5):548-550.
4. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030-1043.
5. Bartram CR, de KA, Hagemeijer A, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306(5940):277-280.
6. Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol. 1997;96(3):601-610.
7. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009;27(31):5175-5181.
8. Kolb EA, Pan Q, Ladanyi M, Steinherz PG. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood. Cancer. 2003;98(12):2643-2650.
9. Ohno R. Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Oncol Rep. 2008;10(5): 379-387.
10. Johnson IS, Armstrong JG, Gorman M, Burnett JP Jr. The vinca alkaloids: a new class of oncolytic agents. Cancer Res. 1963;23:1390-1427.
11. Noble RL, Beer CT, Cutts JH. Role of chance observations in chemotherapy: Vinca rosea. Ann N Y Acad Sci. 1958;76(3):882-894.
12. Silverman JA, Deitcher SR. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol. 2013;71(3):555-564.
13. Jordan MA, Himes RH, Wilson L. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res. 1985;45(6):2741-2747.
14. Jordan MA, Thrower D, Wilson L. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sci. 1992;102 (Pt 3):401-416.
15. Blajeski AL, Phan VA, Kottke TJ, Kaufmann SH. G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J Clin Invest. 2002;110(1):91-99.
16. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 1991;51(8):2212-2222.
17. Mayer LD, St-Onge G. Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques. Anal Biochem. 1995;232(2):149-157.
18. Boman NL, Bally BB, Cullis PR. Encapsulation of vincristine in liposomes reduces its toxicity and improves its anti-tumor efficacy. J Liposome Res. 1995;5(3):523-541.
19. Gidding CE, Kellie SJ, Kamps WA, de GSS. Vincristine revisited. Crit Rev Oncol Hematol. 1999;29(3):267-287.
20. Requena L, Kutzner H. Hemangioendothelioma. Semin Diagn Pathol. 2013;30(1):29-44.
21. Perez J, Pardo J, Gomez C. Vincristine: an effective treatment of corticoid-resistant life-threatening infantile hemangiomas. Acta Oncol. 2002;41(2):197-199.
22. Moore A, Pinkerton R. Vincristine: can its therapeutic index be enhanced? Pediatr Blood Cancer. 2009;53(7):1180-1187.
23. Starke-Peterkovic T, Clarke RJ. Effect of headgroup on the dipole potential of phospholipid vesicles. Eur Biophys J. 2009;39(1):103-110.
24. Bitounis D, Fanciullino R, Iliadis A, Ciccolini J. Optimizing druggability through liposomal formulations: new approaches to an old concept. ISRN Pharm. 2012;2012:738432.
25. Waterhouse DN, Madden TD, Cullis PR, Bally MB, Mayer LD, Webb MS. Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods Enzymol. 2005;391:40-57.
26. Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res. 1990;50(3):575-579.
27. Mayer LD, Nayar R, Thies RL, Boman NL, Cullis PR, Bally MB. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol. 1993;33(1):17-24.
28. Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 1994;54(11):2830-2833.
29. Boman NL, Mayer LD, Cullis PR. Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta. 1993;1152(2):253-258.
30. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991;88(24):11460-11464.
31. Johnstone SA, Masin D, Mayer L, Bally MB. Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta. 2001;1513(1):25-37.
32. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer. 1995;72(4):896-904.
33. O'Brien S, Schiller G, Lister J, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013;31(6):676-683.
34. Yan Z, Zhu ZL, Qian ZZ, et al. Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors. Acta Pharmacol Sin. 2012;33(6):852-858.
35. Krishna R, Webb MS, St Onge G, Mayer LD. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther. 2001;298(3):1206-1212.
36. Silverman JA, Deitcher SR. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol. 2013; 71(3):555-564.
37. Moore AS, Norris R, Price G, et al. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. J Paediatr Child Health. 2011;47(12): 875-882.
38. Thomas DA, Kantarjian HM, Stock W, et al. Phase 1multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer. 2009;115(23):5490-5498.
39. O'Brien S, Thomas DA, Heffner LT, et al. Marqibo® (vincristine sulfate liposomes injection; VSLI) in the treatment of adult patients with advanced, relapsed/refractory acute lymphoblastic leukemia (ALL): a combined analysis of the VSLI-06 and RALLY studies. ASH Annual Meeting Abstracts. 2010;116(21):2143.
40. Bedikian AY, Vardeleon A, Smith T, Campbell S, Namdari R. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. J Clin Pharmacol. 2006;46(7):727-737.
41. Bedikian AY, Silverman JA, Papadopoulos NE, et al. Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. J Clin Pharmacol. 2011;51(8): 1205-1212.
42. Thomas DA, Sarris AH, Cortes J, et al. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer. 2006;106(1):120-127.
43. Peixoto JAA, Teles BC, Castro EF, et al. Vincristine delays gastric emptying and gastrointestinal transit of liquid in awake rats. Braz J Med Biol Res. 2009;42(6):567-573.
44. Ashcroft AJ, Kaplan LD, Damon LE, Morgan GJ. Sphingosomal vincristine plus rituximab for treatment of large B-cell lymphoma. Blood. 2003;102(11):400a-401a.
45. Waterhouse DN, Dos SN, Mayer LD, Bally MB. Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs. Pharm Res. 2001;18(9):1331-1335.
46. Hennipman B, de Vries E, Bokkerink JP, Ball LM, Veerman AJ. Intrathecal vincristine: 3 fatal cases and a review of the literature. J Pediatr Hematol Oncol. 2009;31(11):816-819.
47. Shah NN, Merchant M, Cole D, et al. Vincristine sulfate liposomes injection (VSLI, Marqibo): interim results from a Phase I study in children and adolescents with refractory cancer. Blood (ASH Annual Meeting Abstracts). 2012;120:Abstract 1497.
48. Jessop M, Choo K, Little M. Acute colonic pseudo-obstruction in paediatric oncology patients. J Paediatr Child Health. 2010;46(11):698-699.
49. Talon Therapeutics, Inc. A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥60 Years Old With Newly Diagnosed ALL. Available from: http://clinicaltrials.gov/show/NCT01439347. Accessed October 31, 2013.
50. MD. Anderson Cancer Center. Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia. Available from: http://clinicaltrials.gov/show/NCT01319981. Accessed October 31, 2013.
51. National Cancer Institute (NCI). Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma. Available from: http://clinicaltrials.gov/show/NCT00873093. Accessed October 31, 2013.
52. Talon Therapeutics, Inc. To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents with Refractory Cancer. Available from: http://clinicaltrials.gov/show/NCT01222780. Accessed October 31, 2013.
53. University Hospital, Saarland. OPTIMAL>60, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine. Available form: http://clinicaltrials.gov/show/NCT01478542. Accessed October 31, 2013.
54. Children's Oncology Group. Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma. Available from: http://clinicaltrials.gov/show/NCT01096368. Accessed October 31, 2013.
55. National Cancer Institute (NCI). Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma. Available from: http://clinicaltrials.gov/show/NCT01055314. Accessed October 31, 2013.
56. Talon Therapeutics, Inc. Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma. Available from: http://clinicaltrials.gov/show/NCT00506142. Accessed October 31, 2013.